We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Impact of statins and ACE inhibitors on mortality after COPD exacerbations.
- Authors
Mortensen, Eric M.; Copeland, Laurel A.; Pugh, Mary Jo V.; Restrepo, Marcos I.; De Molina, Rosa Malo; Nakashima, Brandy; Anzueto, Antonio
- Abstract
Background: The purpose of our study was to examine the association of prior outpatient use of statins and angiotensin converting enzyme (ACE) inhibitors on mortality for subjects = 65 years of age hospitalized with acute COPD exacerbations. Methods: We conducted a retrospective national cohort study using Veterans Affairs administrative data including subjects =65 years of age hospitalized with a COPD exacerbation. Our primary analysis was a multilevel model with the dependent variable of 90-day mortality and hospital as a random effect, controlling for preexisting comorbid conditions, demographics, and other medications prescribed. Results: We identified 11,212 subjects with a mean age of 74.0 years, 98% were male, and 12.4% of subjects died within 90-days of hospital presentation. In this cohort, 20.3% of subjects were using statins, 32.0% were using ACE inhibitors or angiotensin II receptor blockers (ARB). After adjusting for potential confounders, current statin use (odds ratio 0.51, 95% confidence interval 0.40-0.64) and ACE inhibitor/ARB use (0.55, 0.46-0.66) were significantly associated with decreased 90-day mortality. Conclusion: Use of statins and ACE inhibitors prior to admission is associated with decreased mortality in subjects hospitalized with a COPD exacerbation. Randomized controlled trials are needed to examine whether the use of these medications are protective for those patients with COPD exacerbations.
- Subjects
STATINS (Cardiovascular agents); ACE inhibitors; MORTALITY; OBSTRUCTIVE lung diseases patients; OUTPATIENT medical care
- Publication
Respiratory Research, 2009, Vol 10, p1
- ISSN
1465-9921
- Publication type
Article
- DOI
10.1186/1465-9921-10-45